Scientists discovered that a sugar produced by a gut bacterium increases energy burning in visceral fat while reducing weight gain and improving metabolic health.
Researchers identified the microbe, Clostridium immunis, living in the human gut. The findings were published in Cell Host & Microbe in November 2026.
The discovery arrives as global health concerns mount regarding rising obesity rates. Half of the world’s population is expected to be overweight or obese by 2035. In Singapore, over 12 percent of the population lives with obesity.
Researchers from Duke-NUS Medical School and Duke University School of Medicine conducted the work. They found that C. immunis produces an exopolysaccharide sugar molecule. This sugar requires phosphocholine for activity. The modified sugar acts as an on switch that catalyzes the reduction of weight gain and visceral fat.
Visceral Fat Reduction
Visceral fat accumulates around internal organs and links closely to metabolic diseases like type 2 diabetes and cardiovascular disease. Examining metagenomic data from 4,145 people globally, the team established the critical role of phosphocholine-modified molecules. People with obesity had fewer copies of the gene that adds phosphocholine compared to individuals with a body mass index below 25.
“What surprised us was that this bacterial sugar did not work by reducing food intake or increasing activity,” said Dr. Tan Chin Yee, first author of the study and a researcher currently with the SingHealth Internal Medicine Residency Programme. “Instead, it changed how visceral fat used energy. That gives us a completely different way of thinking about how gut bacteria can influence metabolism.”
Further investigation showed that the phosphocholine-modified exopolysaccharide reduced levels of the IL-22 protein. This protein helps the immune system communicate with tissues in the small intestine and visceral fat. The reduction increased cells containing the UCP1 protein, which helps fat cells release energy as heat.
Metabolic Treatment Path
Higher UCP1 levels generate greater energy burn in visceral fat. This specific tissue is typically resistant to signals that prompt fat cells to burn energy. The team confirmed that the energy expenditure shift did not stem from reduced food intake or physical activity.
“Our findings reveal how some gut bacteria are able to uniquely communicate with the human body—they generate distinctive molecules by chemically modifying the sugars they produce,” said Assistant Professor Neeraj Surana from the Department of Pediatrics at Duke University School of Medicine. “This opens up a new perspective on how the microbiome can influence human metabolism and points to new opportunities for developing treatments for metabolic diseases.”
Professor Sheemei Lok, interim vice dean for research at Duke-NUS, said that the work moves science beyond simple microbiome associations with obesity. The research isolates a specific molecule and a therapeutic pathway. Researchers have filed a patent on the discovery and are planning clinical trials in the United States.
Common Bacterial Sugar Questions
What is Clostridium immunis?
Clostridium immunis is a bacterium that lives in the human gut. Researchers identified that it produces an exopolysaccharide sugar molecule requiring phosphocholine for activity.
How does the bacterial sugar burn fat?
The phosphocholine-modified sugar reduces IL-22 protein levels in the small intestine and visceral fat. This reduction increases UCP1 protein cells, which cause fat cells to release energy as heat specifically in visceral fat.
Duke-NUS Medical School, Singapore’s second medical school, was established in April 2005 as a collaboration between Duke University and the National University of Singapore. It follows the American post-baccalaureate model, awarding joint degrees from both institutions. In May 2009, the school moved to the Outram campus of Singapore General Hospital, where it later partnered with SingHealth to form the SingHealth Duke-NUS Academic Medical Centre, integrating research with clinical care.
What are the next steps for the research?
The research team filed a patent on the discovery of the bacterium and its sugar. Scientists are now planning clinical trials in the United States to evaluate the approach for treating obesity.